<DOC>
	<DOCNO>NCT00002100</DOCNO>
	<brief_summary>To assess safety tolerance curdlan sulfate , well anti-HIV activity , HIV-infected patient CD4 T-lymphocytes le 500 cells/mm3 , use first single dos , FDA review , daily dose 7 day .</brief_summary>
	<brief_title>Phase I/II Study Curdlan Sulfate</brief_title>
	<detailed_description>In Phase I study , escalate single dos intravenous curdlan sulfate test . In Phase II , curdlan sulfate administer daily 7 day . ( NOTE : Phase I complete . )</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Curdlan sulfate</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV seropositivity . No current AIDSdefining opportunistic infection , lymphoma , Kaposi 's sarcoma , malignancy . CD4 count &lt; 500 cells/mm3 . No critical illness would shorten life expectancy &lt; 16 week . Exclusion Criteria Concurrent Medication : Excluded : Antiretroviral experimental therapy . Anticoagulants . Steroids . Cytotoxic immunosuppressive agent . Concurrent Treatment : Excluded : Radiotherapy . Patients follow prior condition exclude : History heparin sensitivity . Prior Medication : Excluded within 1 month prior study entry : Antiretroviral experimental therapy . Anticoagulants . Steroids . Cytotoxic immunosuppressive agent . Prior Treatment : Excluded : Radiotherapy within 1 month prior study entry . Active IV drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 1994</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>curdlan sulfate</keyword>
</DOC>